RAPT: Utang jangka cendhak perusahaan RAPT Therapeutics

RAPT Therapeutics, Inc. (RAPT) specializes in developing innovative tools to strengthen immune defense. The quotes provided below on GURU.Markets capture the 0.00 metric. The company is implementing automated molecule screening to accelerate drug discovery. However, a lack of profitability and the risk of trial termination due to adverse reactions render the issuer's financial position extremely vulnerable and unstable.

Short-term debts reflect the total obligations of the company with a maturity of up to one year. An increase in this metric indicates rising borrowing costs and a risk of liquidity shortages. By analyzing the company's short-term liabilities, an investor assesses the resilience of the liability structure to external shocks. For RAPT Therapeutics, Inc. (RAPT), this is critical during raw material supply disruptions. A stable chart minimizes the threat of cash flow gaps when conducting costly clinical trials.